Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related ...

Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...

The Chinese biotech evaluated three different once-daily doses of its oral GLP-1 agonist, dubbed ASC30, in a phase 2 study of ...

Imagine if losing weight were as simple as swallowing a daily pill-no needles, no injections and no anxiety. If you're among ...

GLP-1 medicines cause malnutrition in 22% of patients. Multivitamins are often inadequate. Patients need dietitian support ...

At this year’s meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Eli Lilly sought to bolster the case for its oral GLP-1 orforglipron, showcasing more of the drug's ...

At the 13-week primary endpoint, ASC30 once-daily tablets showed dose-dependent placebo-adjusted mean body weight reductions of 5.4%, 7.0% and 7.7% for 20 mg, 40 mg and 60 mg, respectively. No plateau ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. For the first time, a generic GLP-1 has been approved by ...

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared ...

On the heels of striking a deal with the Trump administration to reduce the prices of several of its most popular drugs for U.S. patients, Eli Lilly has unveiled additional savings for cash-paying ...

CHENNAI: Novo Nordisk has introduced Ozempic, its once-weekly injectable semaglutide, to the Indian market on Friday.

Novo Nordisk submitted a higher-dose version of semaglutide (Wegovy) to the FDA for approval as a weight-management treatment ...